Fathima, Parveen http://orcid.org/0000-0002-4516-4127
Jones, Mark http://orcid.org/0000-0003-1736-1702
D’Souza, Reena
Totterdell, James http://orcid.org/0000-0002-9459-2566
Andric, Nada
Abbott, Penelope http://orcid.org/0000-0003-4865-4823
Norman, Richard http://orcid.org/0000-0002-3112-3893
Howard, Kirsten
Cheng, Wendy
Pedrana, Alisa http://orcid.org/0000-0002-1998-5722
Doyle, Joseph S. http://orcid.org/0000-0001-7198-0833
Davies, Jane
Snelling, Thomas http://orcid.org/0000-0003-4670-0638
Funding for this research was provided by:
2020 Medical Research Future Fund - PPHR Initiative - Efficient use of existing medicines (2007164)
Article History
Received: 28 February 2024
Accepted: 30 May 2024
First Online: 17 June 2024
Declarations
:
: This study was approved by the Sydney Local Health District Human Research Ethics committee (Ref: 2022/ETH0168).
: Not applicable as individual level data or potential identifying attributes will not be included in any published material. The participant information materials and informed consent forms are available from the authors on request.
: AP reports investigator-initiated funding to their institution from Gilead Sciences, AbbVie and Merck. AP also reports honoraria to their institution from Gilead Sciences. JSD has received research funding to his institution from Gilead Sciences and AbbVie, and honoraria from AbbVie to his institution. All other authors declare that they have no competing interests.